Poly (adenosine diphosphate-ribose) polymerase inhibitors such as olaparib take advantage of this defect by indirectly increasing the amount of unrepaired DNA double-strand breaks in BRCA1/2-mutated cancer cells through inhibition of the base excision repair pathway, ultimately leading to cell death.2 Here, BRCA1 is linked to cancer.